Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Allergan | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Allergan

Specialty pharma sales up 10% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Allergan
 
1Q Revenues: $1.6 billion (+13%)

1Q Earnings: $257.9 million (earnings were $14.4 million in 1Q13)

Comments: Specialty pharmaceuticals sales increased 10% to $1.4 billion, with Eye Care Pharmaceutical sales of $730.4 million, up 9%, and Botox/Neuromodulators sales up 10% to $501.8 million. Medical devices sales increased 29% to $259.8 million. Earnings in 1Q13 include $258.6 million from discontinued operations associated with the sale of the obesity intervention business unit. On April 22, Allergan received an unsolicited proposal from Valeant Pharmaceuticals to acquire all outstanding shares of Allergan for approximately $47 billion. The Allergan board is currently reviewing the proposal.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters